Search Results - olesia+gololobova

1 Results

Sort By:

Culture-derived EVs for targeted delivery and treatment of B cell diseases

Value Proposition· Purified EVs with preferential targeting for B cells in both ex-vivo and in-vivo applications.· EVs have half-life between 30-40 minutes, longer than many comparable extracellular vesicles.· EVs purified from cell culture medium to increase throughput, speed, and development of B-cell targeted therapies. Technology...

Published: 3/14/2025 | Inventor(s): Kenneth Witwer, Tom Driedonks, Erin Shirk, Linglei Jiang, Olesia Gololobova

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms